首页> 外文期刊>The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics >characterization of (2S,4R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V_(1b) Receptor An
【24h】

characterization of (2S,4R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), a Selective and Orally Active Vasopressin V_(1b) Receptor An

机译:(2S,4R)-1- [5-氯-1-[[2,4-二甲氧基苯基)磺酰基] -3-(2-甲氧基-苯基)-2-氧代-2,3-二氢-1H-的表征吲哚-3-基] -4-羟基-N,N-二甲基-2-吡咯烷羧酰胺(SSR149415),选择性和口服活性加压素V_(1b)受体An

获取原文
获取原文并翻译 | 示例
       

摘要

(2S,4R)-1-[5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxy-phenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl]-4-hydroxy-N,N-dimethyl-2-pyrrolidine carboxamide (SSR149415), the first selective, nonpeptide vasopressin V_(1b) receptor antagonist yet described, has been characterized in vitro and in vivo. SSR149145 showed competitive nanomolr affinity for animal and human V_(1b) receptors and exhibited much lower affinity for rat and human V_(1b), V_2, and oxytocin receptors. Moreover, this compound did not interact with a large number of other receptors, enzymes, or ion channels. In vitro, SSR149145 behaved as a full antagonist and potently inhibited arginine vasopressin (AVP)-induced Ca~(2+) increase in chinese hamster ovary cells expressing rat or human V_(1b) receptors. the in vivo activity of SSR149145 has been studied in several models of elevated corticotropin secretion in conscious rats. SSR149145 inhibited exogenous AVP-indiced increase in plasma corticotropin, from 3 mg/kg i.p. and 10 mg/kg p.o. upwards. Similarly, this compound antagonized AVP-potentiated corticotropin release provoked by exogenous corticoliberin at 3 mg/kg p.o. The effect lasted for more than 4 h at 10 mg/kg p.o. showing a long-lasting oral effect. SSR149145 (10 mg/kg p.o.) also blocked corticotropin secretion induced by endogenous AVP increase subsequent to body water loss. Moreover, 10 mg/kg i.p SSR149415 inhibited plasma corticotropin elevation after restraint-stress in rats by 50%. In the four-plate test, a mouse model of anxiety, SSR149415 (3 mg/kg p.o. upwards) displayed anxiolytic-like activity after acute and 7-day repeated administrations. Thus, SSR149415 is a potent, selective, and orally active V_(1b) receptor antagonist. It represents a unique tool for exploring the functional role of V_(1b) receptors and deserves to be clinically investigated in the field of stress and anxiety.
机译:(2S,4R)-1- [5-氯-1-[[(2,4-二甲氧基苯基)磺酰基] -3-(2-甲氧基-苯基)-2-氧代-2,3-二氢-1H-吲哚- 3-yl] -4-羟基-N,N-二甲基-2-吡咯烷羧酰胺(SSR149415)是第一个尚未描述的选择性非肽加压素V_(1b)受体拮抗剂,已在体外和体内进行了表征。 SSR149145对动物和人V_(1b)受体表现出竞争性的纳摩尔亲和力,对大鼠和人V_(1b),V_2和催产素受体的亲和力低得多。而且,该化合物不与大量其他受体,酶或离子通道相互作用。在体外,SSR149145表现为完全的拮抗剂,并在表达大鼠或人V_(1b)受体的中国仓鼠卵巢细胞中有效抑制了精氨酸加压素(AVP)诱导的Ca〜(2+)增加。 SSR149145的体内活性已经在清醒大鼠中几种促肾上腺皮质激素分泌增加的模型中进行了研究。 SSR149145抑制血浆促肾上腺皮质激素的外源性AVP升高,从腹腔3 mg / kg起。和10 mg / kg p.o.向上。类似地,该化合物拮抗AVP增强的促肾上腺皮质激素释放,该释放是由外源性皮质小球蛋白以3 mg / kg p.o引起的。剂量为10 mg / kg p.o时,效果持续超过4小时。表现出持久的口服效果。 SSR149145(10 mg / kg p.o.)还阻止体内失水后内源性AVP增加引起的促肾上腺皮质激素分泌。此外,10 mg / kg i.p SSR149415抑制大鼠束缚应激后血浆血浆促肾上腺皮质激素的升高达50%。在四板试验中,急性和连续7天重复给药后,焦虑症小鼠模型SSR149415(3 mg / kg p.o.向上)显示出抗焦虑样活性。因此,SSR149415是一种有效的,选择性的,口服活性的V_(1b)受体拮抗剂。它代表了探索V_(1b)受体功能作用的独特工具,值得在应激和焦虑领域进行临床研究。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号